The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.
May 14th 2024
Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Dr. Tam Discusses the DUO Trial for CLL
February 1st 2018Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses, the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Dr. Davids on Results of Obinutuzumab With Ibrutinib in CLL
January 25th 2018Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia (CLL), discusses the initial results of a phase Ib study of ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with relapsed or refractory CLL.
Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL
January 12th 2018Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL
January 6th 2018Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL
January 3rd 2018Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
December 22nd 2017Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).
Dr. Flinn on Venetoclax and Obinutuzumab in CLL
December 12th 2017Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.